文献速递脊柱关节炎

居住地区影响美国银屑病关节炎疾病负担与治疗模式

Where We Live Matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States.
PubMed 文献 · Arthritis Rheumatol · 2026-01-28

基于RISE注册库2020年1月至2023年3月32732例银屑病关节炎患者的横断面研究显示,疾病活动度、社会剥夺和保险覆盖存在地区差异;南部和中西部高疾病活动度与高剥夺指数更常见,中西部糖皮质激素使用较多,少数诊疗机构承担了大量医疗补助和高剥夺患者。

要点

  • 南部和中西部高疾病活动度及高剥夺指数更常见。
  • 中西部患者合并症负担较高(调整OR 1.59,95%CI 0.98-2.59),泼尼松联合传统DMARD使用较多。
  • 女性高疾病活动度常见但生物制剂DMARD使用较少。

核心结论

  • 美国银屑病关节炎的疾病特征和诊疗存在地区差异,部分地区的泼尼松使用高于预期且医疗服务提供者负担不均。
  • 作者认为需进一步研究评估地区诊疗差异对疾病结局的影响。

研究设计与样本

  • 横断面研究,基于RISE注册库2020年1月至2023年3月的32732例银屑病关节炎患者。
  • 评估高疾病活动度(RAPID3>12)、高合并症(RxRisk≥90百分位)、高区域剥夺指数(ADI≥80)、保险覆盖、泼尼松≥10 mg/日及所有DMARD治疗在各地区的分布。
  • 采用逻辑回归模型识别高疾病活动度和合并症的地区相关因素。

主要发现

  • 58.8%为白人女性(平均年龄57.7岁,标准差13.5),60%有私人保险,55.8%居住于南部。
  • 81.8%体重指数≥25,中西部最高(平均32.4,标准差7.8)。
  • 女性和高疾病活动度常见但接受生物制剂DMARD治疗较少。
  • 中西部合并症负担高于东北部(调整OR 1.59,95%CI 0.98-2.59),泼尼松联合传统DMARD使用率为31.3%,东北部20.5%、南部13.6%、西部17.6%。
  • 葡萄膜炎影响1.2%的队列;仅14家(7.1%)和20家(10.1%)RISE诊疗机构分别为半数医疗补助和高剥夺患者提供诊疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US. METHODS: A cross-sectional study of patients with PsA in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March 2023 was conducted. Distribution of high disease activity (HDA; Routine Assessment of Patient Index Data >12), high comorbidity (RxRisk ≥90th percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10 mg daily, and all disease-modifying antirheumatic drug (DMARD) therapies across geographic regions were evaluated. Logistic regression models were used to identify regional correlates of HDA and comorbidity. RESULTS: Of the 32,732 RISE patients with PsA, 58.8% were White women (mean age 57.7 [SD 13.5] years) with private insurance (60%); 55.8% resided in the South. A majority (81.8%) had a body mass index of ≥25, highest in the Midwest (mean 32.4 ± SD 7.8). Women, despite having prevalent HDA, received less biologic DMARD therapy. Both HDA and ADI of ≥80 were more prevalent in the South and Midwest. Compared to the Northeast, Midwest patients had a higher burden of comorbidity (adjusted odds ratio 1.59, 95% confidence interval 0.98 - 2.59) with frequent use of prednisone in conjunction with conventional DMARDs (31.3% vs Northeast 20.5%, South 13.6%, West 17.6%). Uveitis affected 1.2% of the cohort. Only 14 (7.1%) and 20 (10.1%) RISE practices provided care for half of all Medicaid and high-deprivation patients, respectively. CONCLUSION: PsA disease characteristics and care vary across the US, with higher-than-expected prednisone use and unequal provider care burden in some regions. Further work is needed to assess the impact of varied regional care on disease outcomes.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Banbury B, Dowell S, Jenkins C, et al. Where We Live Matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States. Arthritis Rheumatol. 2026. PMID: 40931889. doi:10.1002/art.43377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。